Status:
WITHDRAWN
Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use
Lead Sponsor:
Nova Scotia Health Authority
Conditions:
Adrenergic Pathology
Eligibility:
All Genders
1+ years
Brief Summary
Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice to help in patient management decisions.
Detailed Description
We will be assessing for adverse reactions of patients injected with locally manufactured 123 Iodine MIBG. With monitoring of blood pressure and heart rate following injection and any potential immedi...
Eligibility Criteria
Inclusion
- Patients with potential Adrenergic pathology
Exclusion
- Pregnant or breast feeding females
- Hypersensitivity to MIBG
Key Trial Info
Start Date :
July 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01912040
Start Date
July 1 2006
End Date
December 1 2018
Last Update
November 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Capital District Health Authority
Halifax, Nova Scotia, Canada, B3H2Y5